Display options
Cite
Lachmann PJ. The use of antibodies in the prophylaxis and treatment of infections. Emerg Microbes Infect. 2012;1(8):e11doi: 10.1038/emi.2012.2.
Lachmann, P. J. (2012). The use of antibodies in the prophylaxis and treatment of infections. Emerging microbes & infections, 1(8), e11. https://doi.org/10.1038/emi.2012.2
Lachmann, Peter J. "The use of antibodies in the prophylaxis and treatment of infections." Emerging microbes & infections vol. 1,8 (2012): e11. doi: https://doi.org/10.1038/emi.2012.2
Lachmann PJ. The use of antibodies in the prophylaxis and treatment of infections. Emerg Microbes Infect. 2012 Aug;1(8):e11. doi: 10.1038/emi.2012.2. Epub 2012 Aug 08. PMID: 26038423; PMCID: PMC3630915.
Copy Download .nbib Format: NLM
Share it on

Emerg Microbes Infect. 2012 Aug;1(8):e11. doi: 10.1038/emi.2012.2. Epub 2012 Aug 08.

The use of antibodies in the prophylaxis and treatment of infections.

Emerging microbes & infections

Peter J Lachmann

Affiliations

  1. Department of Veterinary Medicine, University of Cambridge , Cambridge CB3 0ES, UK.

PMID: 26038423 PMCID: PMC3630915 DOI: 10.1038/emi.2012.2

Abstract

The use of antibodies to provide passive immunity to infections has a long history. Although the coming of antibiotics greatly reduced its use for bacterial infections, it is still widely used for a variety of purposes which are reviewed here. The use of animal antisera gave way to the use of human convalescent serum as a source of antibodies and more recently human and monoclonal antibodies have become widely used, not just providing passive immunity but as therapeutic agents. The current uses of antibody therapy are discussed as are the problems of antibody-mediated immunopathology and how this can be avoided. More recent developments include the making of monoclonal antibodies that react with cross-reacting determinants on flu viruses. Such antibodies are not usually made following infection and they provide a very promising approach to providing passive immunity that will be effective against a variety of different strains of the flu virus. It is also pointed out that passive immunotherapy can act as a surrogate vaccine providing that the subject gets infected while protected by the passive antibodies. Finally, there is a section on the possible use of oral antibodies given as food to prevent diseases such as infantile gastroenteritis.

Keywords: antibodies; flu; infection

References

  1. Ann Intern Med. 2006 Oct 17;145(8):599-609 - PubMed
  2. Am J Epidemiol. 1979 Aug;110(2):105-23 - PubMed
  3. J Gen Virol. 1990 Sep;71 ( Pt 9):1975-83 - PubMed
  4. PLoS One. 2008;3(12):e3942 - PubMed
  5. Am J Epidemiol. 2009 Feb 1;169(3):382-8 - PubMed
  6. N Engl J Med. 2006 Sep 7;355(10):1018-28 - PubMed
  7. Transgenic Res. 2000;9(4-5):305-20 - PubMed
  8. Clin Infect Dis. 2011 Feb 15;52(4):447-56 - PubMed
  9. Adv Virus Res. 2003;60:421-67 - PubMed
  10. Biochim Biophys Acta. 1999 Apr 12;1431(1):37-46 - PubMed
  11. J Immunol. 2004 Aug 1;173(3):1978-86 - PubMed
  12. PLoS Pathog. 2010 Feb 12;6(2):e1000790 - PubMed
  13. Science. 2008 Aug 15;321(5891):974-7 - PubMed
  14. Nat Struct Mol Biol. 2009 Mar;16(3):265-73 - PubMed
  15. Immunology. 1972 Feb;22(2):185-97 - PubMed
  16. PLoS One. 2010 Feb 08;5(2):e9106 - PubMed
  17. Nature. 1993 Jun 3;363(6428):446-8 - PubMed
  18. Nature. 1975 Aug 7;256(5517):495-7 - PubMed
  19. Am Heart J. 1963 Mar;65:426-7 - PubMed
  20. Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1771-6 - PubMed
  21. Science. 2010 May 7;328(5979):745-8 - PubMed
  22. Semin Nucl Med. 2010 May;40(3):190-203 - PubMed

Publication Types